Eton Pharmaceuticals (ETON) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Teva Pharmaceutical Industries (TEVA) over the past year, gaining 159.5% versus a gain of 95.2%. Over five years, ETON leads with a +953.4% price change compared with +304.8% for TEVA. Teva Pharmaceutical Industries is the larger company by market cap ($45.78 billion vs $1.56 billion), about 29.3 times the size.
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.7x vs 21.2x for Eton Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | TEVA |
|---|---|---|
| Share price | $54.75 | $39.25 |
| Market cap | $1.56B | $45.78B |
| 1-day change | -0.24% | +0.18% |
| YTD return | +224.54% | +25.54% |
| 1-year return | +159.48% | +95.22% |
| 5-year return | +953.36% | +304.75% |
| P/E ratio (TTM) | 136.88 | 65.42 |
| Forward P/E | 21.22 | 12.70 |
| EPS (TTM) | $0.40 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.26B |
| Revenue growth (YoY) | — | +4.32% |
| Net income (latest FY) | — | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | — | 12.50% |
| Net margin | — | 8.17% |
| 52-week high | $66.37 | $40.79 |
| 52-week low | $14.27 | $18.83 |
| Distance from 52-week high | -17.51% | -3.78% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +29.68% | +15.41% |
| Average volume | 606.07K | 5.29M |
| Shares outstanding | 28.58M | 1.17B |
| Employees | 44 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 29.3 times larger than Eton Pharmaceuticals by market value ($45.78B vs $1.56B).
- ETON has outperformed TEVA by 64.3 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (136.9x vs 65.4x trailing P/E).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
ETON vs TEVA FAQ
Which is bigger, Eton Pharmaceuticals or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.78B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or TEVA?
ETON returned +159.48% over the past 12 months, compared with +95.22% for TEVA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or TEVA?
TEVA has the lower trailing P/E at 65.4, versus 136.9 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Eton Pharmaceuticals and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.